RxDoctor Payments Data

Gordon Newsom, MD

Internal Medicine · Elgin, ILNPI 1508929480

Payments from drug & device makers

$1,005in general payments, 2019–2025

Across 39 payments — averaging $25.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$218
  • AbbVie$209
  • Novo Nordisk$196
  • Pfizer$141
  • Amarin Pharma, Inc.$45
  • Johnson & Johnson$30
  • plus $166 from 8 others

What the payments were for

  • Food & beverage$1,005100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,005 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$171,925
Medicare patients
446
Services billed
1,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban40$47,808
EliquisApixaban33$36,610
FarxigaDapagliflozin Propanediol26$36,188
OzempicSemaglutide23$22,870
JardianceEmpagliflozin20$18,367
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$16,159
Combivent RespimatIpratropium/Albuterol Sulfate12$5,763
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,858
Levothyroxine Sodium273$3,376
Atorvastatin Calcium356$3,372
Metoprolol Succinate146$2,950
Midodrine Hcl14$2,754
Amlodipine Besylate251$1,974
Rosuvastatin Calcium101$1,954
Losartan Potassium201$1,772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$30$47,80840 claims
PfizerEliquis$141$36,61033 claims
AstraZenecaFarxiga$27$36,18826 claims
Boehringer IngelheimJardiance, Combivent Respimat$13$24,13032 claims
Novo NordiskOzempic$196$22,87023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Elgin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →